Tyrosine kinases

MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis

Retrieved on: 
Tuesday, July 27, 2021

Janus Kinases (JAKs) are enzymes found in cells in the immune system that are critical for the cell signaling process.

Key Points: 
  • Janus Kinases (JAKs) are enzymes found in cells in the immune system that are critical for the cell signaling process.
  • That is only a fraction of the total market for anti-inflammatory drugs.
  • The FDA has issued Boxed Warnings for one of the marketed JAK inhibitor drugs used in the comparative study.
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms.

Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

Retrieved on: 
Wednesday, July 14, 2021

Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients.

Key Points: 
  • Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients.
  • Galapagos evaluated GLPG3667, a proprietary selective TYK2 compound, in a randomized, placebo-controlled, double-blind Phase 1b study in 31 patients with diagnosis of moderate to severe plaque psoriasis.
  • Main objectives were to evaluate the safety and tolerability of GLPG3667 as well as signs of clinical activity at Week 4.
  • Based on these results, we aim to initiate a global Phase 2b program in psoriasis next year as part of a program to develop our selective oral TYK2 inhibitor GLPG3667 broadly in inflammatory indications.

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis

Retrieved on: 
Tuesday, July 13, 2021

For over 30 years, Biogen has led in MS research and today has a leading portfolio of MS products.

Key Points: 
  • For over 30 years, Biogen has led in MS research and today has a leading portfolio of MS products.
  • BTK inhibitors may have the potential to transform the treatment paradigm of autoimmune diseases, in particular MS.
  • Orelabrutinib is a small molecule Brutons tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases.
  • Among myeloid cells expressing BTK, microglia, which reside in the CNS, have been shown to express high level of BTK in multiple sclerosis.

TYK2 Kinase Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021

The "TYK2 Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TYK2 Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "TYK2 kinase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TYK2 kinase inhibitors pipeline landscape.
  • This segment of the report provides insights about the different TYK2 kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • TYK2 kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Insights on the Myeloproliferative Neoplasm Drugs Global Market to 2027 - Featuring Gamida Cell, Sierra Oncology & CTI BioPharma Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, June 28, 2021

The "Myeloproliferative Neoplasm Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myeloproliferative Neoplasm Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The various drug classes indicated for the treatment of myeloproliferative neoplasm are demethylation agents, tyrosine kinase inhibitor, multikinase inhibitors, JAK2 inhibitor, and others.
  • Key companies are focusing on strategies such as mergers and acquisitions, which is expected to drive the global myeloproliferative neoplasm drugs market growth.
  • Moreover, key players are focusing on product launches and product approvals to strengthen their presence in the global myeloproliferative neoplasm drugs market.

InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL

Retrieved on: 
Monday, June 28, 2021

BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL).

Key Points: 
  • BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL).
  • Orelabrutinib is a highly selective BTK inhibitor targeting both B-cell malignancy and autoimmune diseases.
  • Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare said, "We are very proud that orelabrutinib was granted BTD after obtaining Orphan Drug Designation.
  • InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases.

European Hematology Association - ALPINE Study Reveals Superior Safety and Efficacy of Zanubrutinib Compared with Ibrutinib

Retrieved on: 
Friday, June 11, 2021

Zanubrutinib is a next-generation BTK inhibitor that is designed for potent and sustained inhibition of BTK while minimizing the off-target effects of first-generation inhibitors such as ibrutinib.

Key Points: 
  • Zanubrutinib is a next-generation BTK inhibitor that is designed for potent and sustained inhibition of BTK while minimizing the off-target effects of first-generation inhibitors such as ibrutinib.
  • The activity and tolerability of zanubrutinib have been demonstrated in patients with CLL/SLL in early phase clinical trials.
  • The ALPINE study solidifies the findings of these pivotal trials by a head-to-head comparison of the safety and efficacy of zanubrutinib and ibrutinib in 415 patients with relapsed/refractory CLL/SLL.
  • In summary, zanubrutinib showed more selective inhibition of BTK resulting in improved efficacy and safety compared with ibrutinib.

European Hematology Association - ALPINE Study Reveals Superior Safety and Efficacy of Zanubrutinib Compared with Ibrutinib

Retrieved on: 
Friday, June 11, 2021

Zanubrutinib is a next-generation BTK inhibitor that is designed for potent and sustained inhibition of BTK while minimizing the off-target effects of first-generation inhibitors such as ibrutinib.

Key Points: 
  • Zanubrutinib is a next-generation BTK inhibitor that is designed for potent and sustained inhibition of BTK while minimizing the off-target effects of first-generation inhibitors such as ibrutinib.
  • The activity and tolerability of zanubrutinib have been demonstrated in patients with CLL/SLL in early phase clinical trials.
  • The ALPINE study solidifies the findings of these pivotal trials by a head-to-head comparison of the safety and efficacy of zanubrutinib and ibrutinib in 415 patients with relapsed/refractory CLL/SLL.
  • In summary, zanubrutinib showed more selective inhibition of BTK resulting in improved efficacy and safety compared with ibrutinib.

Aptose to Hold Corporate Update Friday, June 11th

Retrieved on: 
Thursday, May 27, 2021

SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress.

Key Points: 
  • SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress.
  • The event will include an up-to-date review of clinical data available for Aptoses clinical programs: luxeptinib (CG-806), Aptoses oral, first-in-class FLT3 and BTK kinase inhibitor in two Phase 1 a/b trials, one in patients with relapsed or refractory acute myeloid leukemia (AML) and another in patients with relapsed or refractory B cell malignancies; and APTO-253, a first-in-class small molecule MYC repressor in a Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndromes (MDS).

Kronos Bio Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 26, 2021

The fireside chats will be webcast live from the Investors & Media section of the companys website at www.kronosbio.com .

Key Points: 
  • The fireside chats will be webcast live from the Investors & Media section of the companys website at www.kronosbio.com .
  • Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.
  • Kronos Bio is developing a portfolio of spleen tyrosine kinase (SYK) inhibitors, entospletinib (ENTO) and lanraplenib (LANRA), for the treatment of NPM1-mutated and FLT3-mutated acute myeloid leukemia (AML).
  • Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.